Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV

Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) an...

Full description

Bibliographic Details
Main Authors: Hiva Azizi, Jason P. Knapp, Yue Li, Alice Berger, Marc-Alexandre Lafrance, Jannie Pedersen, Marc-Antoine de la Vega, Trina Racine, Chil-Yong Kang, Jamie F. S. Mann, Jimmy D. Dikeakos, Gary Kobinger, Eric J. Arts
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Vaccines
Subjects:
human immunodeficiency virus type 1 (HIV-1)
vesicular stomatitis virus (VSV) vector
HIV-1 Envelope glycoprotein
Ebola virus glycoprotein
Online Access:https://www.mdpi.com/2076-393X/11/5/977

Internet

https://www.mdpi.com/2076-393X/11/5/977

Similar Items